Novartis AG
SIX:NOVN
Novartis AG
SIX:NOVN
Price:
89.34 CHF
1.41%
Updated:
May 7, 2024
Novartis AG
Cash from Financing Activities
|
Novartis AG
Cash from Financing Activities Peer Comparison
Comparables:
NLSP
ROG
S
SDZ
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Novartis AG
SIX:NOVN
|
Cash from Financing Activities
-$14.3B
|
CAGR 3-Years
-86%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-5%
|
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Cash from Financing Activities
$17.4m
|
CAGR 3-Years
249%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Roche Holding AG
SIX:ROG
|
Cash from Financing Activities
-CHf4.2B
|
CAGR 3-Years
24%
|
CAGR 5-Years
17%
|
CAGR 10-Years
12%
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Cash from Financing Activities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Novartis AG's Cash from Financing Activities?
Cash from Financing Activities
-14.3B
USD
-14.3B
USD
Based on the financial report for Dec 31, 2023, Novartis AG's Cash from Financing Activities amounts to -14.3B USD.
What is Novartis AG's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-5%
-5%
Over the last year, the Cash from Financing Activities growth was 31%. The average annual Cash from Financing Activities growth rates for Novartis AG have been -86% over the past three years , -27% over the past five years , and -5% over the past ten years .
You don't have any saved screeners yet
